Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 34c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Eagle Pharmaceuticals Reports Second Quarter 2020 Results
August 10, 2020 6:50 AM EDT-- Q2 2020 net loss was ($0.02) per basic and diluted share and adjusted non-GAAP net income was $0.59 per basic and $0.57 per diluted share --
-- Anticipate launch of vasopressin, maintaining our 180-day market exclusivity --
-- CMS establishes unique J-code for PEMFEXY (pemetrexed for injection); FDA granted supplement approval for 500mg multiple-dose vial --
-- Received positive additional data for the Companys fulvestrant product candidate, EA-114, for HR-positive advanced breast cancer --
-- Received a Complete Response Letter for NDA for... More
